Prognostic significance of the expression of Smad4 and Smad7 in human gastric carcinomas

Annals of Oncology

Volumn 15, Issue 4, 2004, Pages 574-580

  Kim, Y H ^a   Lee, H S ^a   Lee, H J ^a   Hur, K ^a   Kim, W H ^a   Bang, Y J ^a   Kim, S J ^b   Lee, K U ^a   Choe, K J ^a   Yang, H K ^a  

^a Seoul National University College of Medicine   (South Korea)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Gastric carcinoma; Prognostic factor; Smad4; Smad7; Transforming growth factor

Indexed keywords

SMAD4 PROTEIN; SMAD7 PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER INVASION; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE; STOMACH CARCINOMA; TUMOR VOLUME;

EID: 2342434705     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdh131     Document Type: Article

References (30)

1. Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor β in human disease. N Engl J Med 2000; 342: 1350-1358.
2. Derynck R, Gelbart WM, Harland RM et al. Nomenclature: vertebrate mediators of TGF β family signals. Cell 1996; 87: 173.
3. Savage C, Das P, Finelli AL et al. Caenorhabditis elegans genes sma-2, sma-3, and sma-4 define a conserved family of transforming growth factor beta pathway components. Proc Natl Acad Sci USA 1996; 93: 790-794.
4. Attisano, L, Wrana JL. Smads as transcriptional co-modulators. Curr Opin Cell Biol 2000; 12: 235-243.
5. Massagué J, Wotton D. Transcriptional control by the TGF-β/Smad signaling system. EMBO J 2000; 19: 1745-1754.
6. White RL. Tumor suppressing pathways. Cell 1998; 92: 591-592.
7. Hahn SA, Schutte M, Hoque AT et al. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 1996; 271: 350-353.
8. MacGrogan D, Pegram M, Slamon D, Bookstein R. Comparative mutations analysis of DPC4 (Smad4) in prostatic and colorectal carcinomas. Oncogene 1997; 15: 1111-1114.
9. Schutte M, Hruban RH, Hedrick L et al. DPC4 gene in various tumor types. Cancer Res 1996; 56: 2527-2530.
10. Kim SK, Fan Y, Papadimitrakopoulou V et al. DPC4, a candidate tumor suppressor gene, is altered infrequently in head and neck squamous cell carcinoma. Cancer Res 1996; 56: 2519-2521.
11. Lei J, Zou TT, Shi YQ et al. Infrequent DPC4 gene mutation in esophageal cancer, gastric cancer and ulcerative colitis-associated neoplasms. Oncogene 1996; 13: 2459-2462.
12. Takagi Y, Kohmura H, Futamura M et al. Somatic alterations in the DPC4 gene in human colorectal cancers in vivo. Gastroenterology 1996; 111: 1369-1372.
13. de Manzoni G, Tomezzoli A, Di Leo A et al. Clinical significance of mutator phenotype and chrpmosome 17q and 18q allelic loss in gastric cancer. Br J Surg 2001; 88: 419-425.
14. Natsugoe S, Xiangming C, Matsumoto M et al. Smad4 and transforming growth factor β1 expression in patients with squamous cell carcinoma of the esophagus. Clin Cancer Res 2002; 8: 1838-1842.
15. Tascilar M, Skinner HG, Rosty C et al. The Smad4 protein and prognosis of pancreatic ductal adenocarcinoma. Clin Cancer Res 2001; 7: 4115-4121.
16. Kang YK, Kim WH, Jang JJ. Expression of G1-S modulators (p53, p16, p27, cyclin D1, Rb) and Smad4/Dpc4 in intrahepatic cholangiocarcinoma. Hum Pathol 2002; 33: 877-883.
17. Xiangming C, Natsugoe S, Takao S et al. Preserved Smad4 expression in the transforming growth factor in patients with advanced gastric cancer. Clin Cancer Res 2001; 7: 277-282.
18. Afrakhte M, Moren A, Jossan S et al. Induction of inhibitory Smad6 and Smad7 mRNA by TGF-β family members. Biochem Biophys Res Commun 1998; 249: 505-511.
19. Kleeff J, Ishiwata T, Maruyama H et al. The TGF-β signaling inhibitor Smad7 enhances tumorigenicity in pancreatic cancer. Oncogene 1999; 18: 5363-5372.
20. Roijer E, Moren A, ten Dijke P, Stenman G. Assignment of the Smad7 gene (MADH7) to human chromosome 18q21.1 by fluorescence in situ hybridization. Cytogenet Cell Genet 1998; 81: 189-190.
21. Boulay JL, Mild G, Reuter J et al. Combined copy status of 18q21 genes in colorectal cancer shows frequent retention of SMAD7. Genes Chromosom Cancer 2001; 31: 240-247.
22. Wilentz RE, Su GH, Dai JL et al. Immunohistochemical labeling for Dpc4 mirrors genetic status in pancreatic adenocarcinomas: A new marker of DPC4 inactivation. Am J Pathol 2000; 156: 37-43.
23. Sandusky G, Berg DT, Richardson MA et al. Modulation of thrombomodulin-dependent activation of human protein C through differential expression of endothelial Smads. J Biol Chem 2002; 277: 49815-49819.
24. Sobin LH, Wittekind CH. In Hermanek P, Sobin LH (eds): TNM Classification of Malignant Tumors (UICC. S), 6th edition. New York: Wiley-Liss 2002; 65-68.
25. Attisano L, Wrana JL. Mads and Smads in TGF β signaling. Curr Opin Cell Biol 1998; 10: 188-194.
26. Itoh S, Landstrom M, Hermansson A et al. Transforming growth factor β1 induces nuclear export of inhibitory Smad7. J Biol Chem 1998; 273: 29195-29201.
27. Uchino S, Tsuda H, Noguchi M et al. Frequent loss of heterozygosity at the DCC locus in gastric cancer. Cancer Res 1992; 52: 3099-3102.
28. Lee HS, Lee HK, Kim HS et al. Tumor suppressor gene expression correlates with gastric cancer prognosis. J Pathol 2003; 200: 39-46.
29. Nakao A, Afrakhte M, Moren A et al. Identification of Smad7, a TGF-β-inducible antagonist of TGF-β signaling. Nature 1997; 389: 631-635.
30. Monteleone G, Kumberova A, Croft NM et al. Blocking Smad7 restores TGF-β1 signaling in chronic inflammatory bowel disease. J Clin Invest 2001; 108: 601-609.